07:00 , Jul 21, 2008 |  BC Week In Review  |  Company News

EpiCept, GNI Ltd. deal

GNI received a license to develop and commercialize EpiCept’s EP1013 for late-stage viral hepatitis in Asia, Australia and New Zealand. The small molecule inhibitor of caspases is in preclinical development in the indication. GNI’s F351...
08:00 , Dec 17, 2007 |  BC Week In Review  |  Clinical News

F351: Phase I start

GNI will begin a Chinese Phase I trial of oral F351. GNI Ltd. (Tokyo:2160), Tokyo, Japan   Product: F351   Business: Hepatic   Molecular target: NA   Description: Small molecule non-steroidal anti-fibrosis compound   Indication:...
07:00 , Jun 27, 2005 |  BC Week In Review  |  Company News

GNI, Shanghai Genomics Inc. deal

GNI will merge with Shanghai Genomics. GNI has R&D programs in infectious disease, cardiovascular disease, inflammation and cancer. Shanghai Genomics has filed an IND in China for F351 , a small molecule non-steroidal anti-fibrosis compound....
01:26 , Jun 21, 2005 |  BC Extra  |  Financial News

GNI raises $13M

GNI (Tokyo, Japan) raised $13 million in a private equity round led by Nomura, Healthcare Partners and undisclosed U.S. and Japanese private equity firms. GNI also said it will merge with Shanghai Genomics (Shanghai, China)....